We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 15, 2021

Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma

Annals of Oncology

 

Additional Info

Annals of Oncology
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006
Ann. Oncol 2021 Oct 25;[EPub Ahead of Print], GV Long, A Arance, L Mortier, P Lorigan, C Blank, P Mohr, J Schachter, JJ Grob, M Lotem, MR Middleton, B Neyns, N Steven, A Ribas, E Walpole, MS Carlino, C Lebbe, M Sznol, E Jensen, MA Leiby, N Ibrahim, C Robert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading